CRISPR Therapeutics (CRSP) Q1 2025 Earnings
How Did CRSP Stock React to Q1 2025 Earnings?
S&P 500 over the same 30 days: +7.22%.
Did CRSP Beat Earnings? Q1 2025 Results
No. CRISPR Therapeutics reported Q1 2025 earnings of $-1.58 a share on May 6, 2025, missing the $-1.28 consensus estimate by 23.7%. Revenue was $865,000 against a $6.0M estimate.
CRISPR Therapeutics delivered a sharply disappointing first quarter, missing on both the top and bottom lines as the gene editing company continues to burn cash across a busy pipeline. The company posted an EPS loss of $1.58, missing the consensus estimate of $1.28 by 23.75%, while revenue of just $865,000, composed entirely of grant income with no collaboration revenue recognized, fell 85.50% short of the $5.96 million Wall Street had expected, even as that figure represented 71.6% growth year-over-year. The net loss widened to $136 million from $116.59 million a year earlier, driven in part by higher collaboration expenses tied to CASGEVY and in vivo HSC editing programs. With <a href="https://247wallst.com/investing/2025/05/05/crispr-therapeutics-crsp-short-sellers-have-a-lot-riding-on-earnings/">significant short interest riding on the outcome</a>, the headline numbers were softened by a genuine clinical bright spot: CTX310 demonstrated dose-dependent LDL and triglyceride reductions of up to 81% and 82%, respectively, across its first 10 patients. Management guided for growing CASGEVY patient initiations through 2025 and flagged CTX320 top-line data as a near-term catalyst expected in Q2.
- Positive Phase 1 clinical data from CTX310 targeting ANGPTL3 for cardiovascular disease
- Continued CASGEVY commercial rollout with more than 65 authorized treatment centers activated globally
- Approximately 90 patients have had cells collected across all regions for CASGEVY
- New reimbursement agreements secured in NHS England, Wales, Austria, and UAE Emirates
- Lower R&D expenses driven by decreased employee-related and stock-based compensation costs
“CRISPR Therapeutics remains focused on executing our strategic priorities and advancing our portfolio of innovative therapies. We are highly encouraged by the initial data from our Phase 1 trial for CTX310, which demonstrates the power of our in vivo gene editing platform to deliver paradigm changing medicines to patients with serious cardiovascular disease.”
CRISPR Therapeutics CEO, on the earnings call
What Was CRISPR Therapeutics's Outlook in Q1 2025?
CASGEVY new patient initiations expected to grow significantly throughout 2025, with commercial production at the Portsmouth, NH facility expected to begin in H2 2025. CTX320 Phase 1 top-line data update on track for Q2 2025. Broad CTX112 updates in oncology and autoimmune diseases expected mid-2025, with CTX131 updates also expected in 2025. CTX310 Phase 1 data presentation anticipated at a medical meeting in H2 2025. Regenerative medicine (Type 1 diabetes) update expected in 2025. Preclinical programs CTX340 and CTX450 continue IND/CTA-enabling studies.
CRSP YoY Financials
| Metric | Q1 2025 | Q1 2024 | Year over year |
|---|---|---|---|
| Revenue | $865,000 | $503,991 | +71.6% |
| Operating Income | −$148.4M | −$157.2M | −5.6% |
| Net Income | −$136.0M | −$163.1M | −16.6% |
CRSP Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.